Therapy of urinary bladder tumors with the aid of the Neodymium-YAG-laser is improved by two following demands. A homogeneous, deep necrosis must be obtained for the tumor cells to be devitalised completely, and neighbouring organs must be protected adequately. Both depth and shape of the necrosis were determined on liver tissue at different conditions, e.g. laser application with air, water and various time/power ratios. Measurements of temperature profiles at the bladder back wall reveal that the parameters necessary for sufficient transmural destruction of bladder tumors do not affect neighbouring organs. In clinical application it is not necessary to control temperatures occurring at the bladder wall during irradiation by means of temperature probes. It is sufficient to adjust the dosis of laser on the basis of superficial, visual discoloration. Carbonisation should be avoided by all means. Comparable effects were obtained by clinical application of data obtained during animal experimentation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Current and Future Role of Circulating DNA in the Diagnosis and Management of Urothelial Carcinoma.
Am Soc Clin Oncol Educ Book
January 2025
Division of Oncology, Department of Medicine, University of Washington, Seattle, WA.
The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in bladder cancer. The National Comprehensive Cancer Network recommends that all patients with stage IVA and stage IVB urothelial carcinoma have molecular analysis that integrates at least testing to help facilitate the selection of future therapeutic options. Sequencing of tumor-derived tissue is the mainstay to obtain this genomic testing, but as in other cancers, there has been extensive research into the integration of liquid biopsies in longitudinal management.
View Article and Find Full Text PDFSonodynamic Therapy by Reactive Oxygen Species Generation-Responsive Pseudo-Semiconducting Polymer Nanoparticles Combined with a Fibroblast Growth Factor Receptor Inhibitor for Enhancing Immunotherapy in Bladder Cancer.
ACS Appl Mater Interfaces
January 2025
Department of Urology/State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Sonodynamic therapy, a treatment modality recently widely used, is capable of disrupting the tumor microenvironment by inducing immunogenic cell death (ICD) and enhancing antitumor immunity during immunotherapy. Erdafitinib, an inhibitor of the fibroblast growth factor receptor, has demonstrated potential benefits for treating bladder cancer. However, Erdafitinib shows effectiveness in only a small number of patients, and the majority of patients responding positively to the medication have "immune-cold" tumors.
View Article and Find Full Text PDFExploring the influence of health and digital health literacy on quality of life and follow-up compliance in patients with primary non-muscle invasive bladder cancer: a prospective, single-center study.
World J Urol
January 2025
School of Medicine, Department of Urology, Istanbul Medeniyet University, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Fahrettin Kerim Gökay Cd., Istanbul, 34720, Turkey.
Objective: Given the increasing significance of digital health literacy (DHL) and health literacy (HL) in promoting informed decision-making and healthy behaviors, this study aimed to assess the influence of self-reported HL and DHL on treatment adherence and quality of life among patients who underwent transurethral resection of bladder tumors (TUR-BT) for primary non-muscle invasive bladder cancer (NMIBC).
Materials & Methods: This single-center observational study involved patients who underwent TUR-BT for NIMBC at a tertiary hospital from May 2022 to February 2024. Before the procedure, the patients' DHL and HL were evaluated using the European Health Literacy Survey Questionnaire short version and the eHealth Literacy Scale.
Natural compounds as modulators of miRNAs: a new frontier in bladder cancer treatment.
Med Oncol
January 2025
Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo, 11829, Egypt.
Bladder cancer (BC) is a major global health issue with a high recurrence rate and limited effective treatments. Over the past few years, it has become evident that miRNAs play a role in the carcinogenesis process, particularly in regulating genes that promote cancer cell proliferation and invasion. This review focuses on the extent to which natural products can act as potential miRNA modulators for the management of bladder cancer.
View Article and Find Full Text PDFUtility of MRI in NMIBC and feasibility of avoiding Re-TURB in carefully selected patients: a systematic review.
World J Urol
January 2025
Department of Urology, Paris Saint-Joseph Hospital, Paris, France.
Objective: This systematic review was conducted to synthesize current research on the role of repeated transurethral resection of the bladder (re-TURB) and the emerging use of magnetic resonance imaging (MRI) in discerning patient suitability for safely foregoing this procedure.
Evidence Acquisition: Employing a methodical literature search, we consulted several bibliographic databases including PubMed, Science Direct, Scopus, and Embase. The review process adhered strictly to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!